Skip to main content

Experimental Drug Slows Decline In Alzheimer’s Patients

By Sponsored

Combined results from two studies show that Solanezumab, an Alzheimer’s drug being developed by Eli Lilly & Co., might slow mental decline, particularly in milder Alzheimer’s cases. The results were announced on Monday by researchers at a conference of the American Neurological Association in Boston.

While the separate studies showed that the drug did not achieve the main goal of slowing the progress of Alzheimer’s significantly, pooled results found that mild Alzheimer’s patients administered with Solanezumab showed a 34 percent smaller decline compared to those given a placebo for 18 months.

While these results are not strong enough for the drug to be approved in the immediate future, they do indicate that by focusing on clearing the sticky deposits that clog the brains of patients, researchers are on the right track.

The most common of the dementia-related diseases, Alzheimer’s affects about 5 million patients in the U.S. alone. With no known cure, the Alzheimer’s medicines in use today like Namenda and Aricept only slow its progress or provide short-term symptom relief.

Solanezumab is one of several drugs currently in the late stages of testing that was designed with the goal of changing the progress of Alzheimer’s.

Each of the two studies involved approximately 1,000 patients in 16 countries with an average age of 75. Two-thirds of the patients had mild Alzheimer’s, while one-third had moderately severe Alzheimer’s.

Progress of Alzheimer’s was mostly measured through two tests, one focused on language, memory and thinking and the other focused on the capacity of the patient to carry out routine activities like eating and grooming. The combined results of patients with mild Alzheimer’s showed close to a 2-point difference in the approximately 90-point score for thinking abilities.

Maria Carillo of the Alzheimer’s Association, which was not involved in the research, described the results as “encouraging,” while stressing that they were by no means the “home run” that the association had been hoping for.

A spokesperson for Lilly said that the company will be contacting the Food and Drug Administration to discuss the next steps.

 Source: CBC

Sponsored

Contributor

Angela is the editor of Activebeat and is an avid health enthusiast. She’s our source for great fitness and exercise tips and is dedicated to bringing you the breaking news stories each day. From recalls and outbreaks to FDA announcements and alerts, she’ll keep you up-to-date with the most important health news every day.

Senior

Explore

What is Eye Movement Desensitization and Reprocessing (EMDR) Therapy?
By Katherine George Your Health

What is Eye Movement Desensitization and Reprocessing (EMDR) Therapy?

EMDR is a fairly new and nontradiational type of psychotherapy. It has become increasingly popular for treating PTSD. To learn more about it, here’s a look into what it is, how it works, if it’s effective, and the potential risks and benefits…

Read More about What is Eye Movement Desensitization and Reprocessing (EMDR) Therapy?

7 min read

Lung Cancer Rates Have Decreased for the Marlboro Man, but Have Risen Steeply for Nonsmokers and Young Women – An Oncologist Explains Why
By Estelamari Rodriguez Your Health

Lung Cancer Rates Have Decreased for the Marlboro Man, but Have Risen Steeply for Nonsmokers and Young Women – An Oncologist Explains Why

When many people think of an average lung cancer patient, they often imagine an older man smoking. But the face of lung cancer has changed. Over the past 15 years, more women, never smokers and younger people are being diagnosed with lung cancer. In fact, lung cancer is the leading cause of cancer death among […]

Read More about Lung Cancer Rates Have Decreased for the Marlboro Man, but Have Risen Steeply for Nonsmokers and Young Women – An Oncologist Explains Why

4 min read

Ultra-Processed Foods – Like Cookies, Chips, Frozen Meals and Fast Food – May Contribute to Cognitive Decline
By Sara N. Burke Your Health

Ultra-Processed Foods – Like Cookies, Chips, Frozen Meals and Fast Food – May Contribute to Cognitive Decline

Scientists have known for years that unhealthy diets – particularly those that are high in fat and sugar – may cause detrimental changes to the brain and lead to cognitive impairment. Many factors that contribute to cognitive decline are out of a person’s control, such as genetics and socioeconomic factors. But ongoing research increasingly indicates […]

Read More about Ultra-Processed Foods – Like Cookies, Chips, Frozen Meals and Fast Food – May Contribute to Cognitive Decline

5 min read